scPharmaceuticals’ pipeline includes multiple products in various stages of clinical and non-clinical development. We focus on proven pharmaceutical products in the cardiovascular and infectious disease therapeutic areas where subcutaneous administration of previously developed intravenous products could provide an alternative for patients and caregivers outside of the acute care setting while improving patient satisfaction and reducing overall healthcare costs, without compromising the quality of care.
Furosemide is a well-known loop diuretic developed in the 1960s. It is one of the most widely used prescription pharmaceuticals in the United States. The use of intravenous furosemide is universally recommended in international guidelines for the management of edema in patients with acute decompensated heart failure due to the highly variable and overall reduction in the bioavailability of oral formulations. A novel, proprietary furosemide solution buffered to a neutral pH for subcutaneous administration via the sc2Wear Furosemide Infusor, has been developed.
Ceftriaxone is one of the most widely-used antibiotics in outpatient parenteral antibiotic therapy (OPAT). Ceftriaxone was approved in 1984 and is used to treat Lyme disease and bacterial, skin, respiratory, bone and joint, and urinary tract infections.
Ertapenem, approved in 2001, is an antibacterial used to manage drug resistant infections which are increasing in incidence and prevalence inside and outside of the hospital setting. It is used in the treatment of complicated intra-abdominal infections, complicated skin and skin structure infections, diabetic foot infections, community acquired pneumonia and complicated urinary tract infections.